You are here

Article Text

Article menu
Download PDFPDF
Letters
Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab

https://doi.org/10.1136/ard.2010.132845

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation.

    • Competing interests AO has received consultant fees from Chugai Pharmaceutical, the manufacture of tocilizumab.

    • Patient consent Obtained.

    • Ethics approval This study was conducted with approval of the Human Research and Ethics Committees at Osaka University Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.